Ovid Therapeutics (OVID) Interest Expenses (2016 - 2026)
Ovid Therapeutics' (OVID) quarterly Interest Expenses came in at $2.3 million in Q1 2026, down 6.84% YoY from $2.5 million in Q1 2025, and down 86.9% on a QoQ basis from $17.6 million in Q3 2025.
Ovid Therapeutics (OVID) Interest Expenses (2016 - 2026) Analysis & Trends
Ovid Therapeutics (OVID) has 11 years of Interest Expenses data on file, last reported at $2.3 million in Q1 2026.
- Quarterly Interest Expenses fell 6.84% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 6.84% YoY) and the FY2025 annual result came in at $91.1 million, up 1.81% from the prior year.
- Interest Expenses retreated to $2.3 million in Q1 2026, from $17.6 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $89.5 million in Q4 2024 to a low of $62158.0 in Q4 2022.
- A 5-year average of $11.5 million and a median of $2.8 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses sank 97.4% — and 2023, when it soared 8286.69%.
- Tracing OVID's Interest Expenses over 5 years: stood at $62158.0 in 2022, then soared by 8286.69% to $5.2 million in 2023, then soared by 1616.36% to $89.5 million in 2024, then tumbled by 80.38% to $17.6 million in 2025, then plunged by 86.9% to $2.3 million in 2026.
- The last three Interest Expenses figures came in at $2.3 million (Q1 2026), $17.6 million (Q3 2025), and $2.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Ovid Therapeutics | 385.37 Mn | 229.84 Mn | - | 2.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.30 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Sep 30, 2025 | 17.56 Mn |
| Sep 30, 2025 | 17.56 Mn |
| Jun 30, 2025 | 2.47 Mn |
| Jun 30, 2025 | 2.47 Mn |
| Mar 31, 2025 | 2.47 Mn |
| Mar 31, 2025 | 2.47 Mn |
| Dec 31, 2024 | 89.47 Mn |
| Dec 31, 2024 | 89.47 Mn |
| Sep 30, 2024 | 2.32 Mn |
| Sep 30, 2024 | 2.32 Mn |
| Jun 30, 2024 | 20.45 Mn |
| Jun 30, 2024 | 20.45 Mn |
| Mar 31, 2024 | 3.85 Mn |
| Mar 31, 2024 | 3.85 Mn |
| Dec 31, 2023 | 5.21 Mn |
| Dec 31, 2023 | 5.21 Mn |
| Sep 30, 2023 | 22.19 Mn |
| Sep 30, 2023 | 22.19 Mn |